How loud is loud enough?

The protests to the pace and structure of Meaningful Use (MU) are getting louder and louder. As has been predicted in the past, if the complaints grow loud enough the government will have to adjust to accommodate.

Can a coalition of 35 medical societies led by the American Medical Association hoping to see changes in the incentive program be loud enough?

The coalition sent a letter to National Coordinator for Health IT Karen DeSalvo, MD, MPH, MSc, saying the program is not working.

“Among physicians there are documented challenges and growing frustration with the way EHRs are performing,” the groups wrote in a nine-page letter. “Many physicians find these systems cumbersome, do not meet their workflow needs, decrease efficiency and have limited, if any, interoperability. Most importantly, certified EHR technology can present safety concerns for patients. We believe there is an urgent need to change the current certification program to better align end-to-end testing to focus on EHR usability, interoperability and safety.”

MU certification requirements are contributing to EHR system problems with “downstream effects” on patient safety, they wrote. Also, providers are prioritizing MU certification “at the expense of meeting physician customers’ needs, patient safety and product innovation.” The coalition is concerned about the “lack of oversight ONC places on authorized testing and certification bodies for ensuring testing procedures and standards are adequate to secure and protect electronic patient information contained in EHRs.”

With the proposed rule for Stage 3 looming, I for one am interested to see how this plays out.

Beth Walsh

Clinical Innovation + Technology editor

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.